THRD News
Archived Headlines
- US IPO Week Ahead: Corebridge plots the year’s largest IPO 09/09/22
- US IPO Weekly Recap: IPO launches trickle in after Labor Day, led by Corebridge’s $1.8 billion deal 09/09/22
- Inflammatory disease biotech Third Harmonic Bio sets terms for $153 million IPO 09/08/22
- US IPO Week Ahead: Quiet IPO calendar primed for post-Labor Day launches 09/02/22
- Rise in secondary offerings hints at IPO market reopening 08/30/22
See more
Nearly 90% of 2022's large IPOs are trading above issue
While market conditions are still keeping the IPO window mostly closed, the year's large issuers are finding support, especially over the past few months. Excluding high-flying outlier HKD, just 15 IPOs have raised $100 million or more in 2022, and 13 (87%)...read more
Updated: Renaissance Capital's 3Q 2022 US IPO Market Review
IPO Market Misfires in the Slowest 3Q in Over a Decade It was the worst third quarter for new issuers in over a decade, with 25 IPOs raising $2.4 billion as the 2022 US IPO market remains on...read more
US IPO Weekly Recap: Billion-dollar deal Corebridge completes 2022’s largest IPO to date
Six issuers began trading this past week, four of which will be included in our stats. The most notable debuts included Corebridge Financial (CRBG) and Third Harmonic Bio (THRD). The pipeline was also active, with seven IPOs...read more
Inflammatory disease biotech Third Harmonic Bio prices upsized IPO at $17 midpoint
Third Harmonic Bio, a Phase 1 biotech developing a therapy for allergic and inflammatory diseases, raised $185 million by offering 10.9 million shares at $17, the midpoint of the $16 to $18 range. The company offered 1.9 million more shares than anticipated. ...read more